ArticleInternational journal of clinical oncology2026
Prior response to anti-VEGF agents predicts the efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTrifluridine/Tipiracil (FTD/TPI) combined with bevacizumab (Bev) is a standard treatment for patients with unresectable metastatic colorectal cancer (mCRC) in later-line therapy. Despite the availability of other drugs like regorafenib and fruquintinib, there is no consensus on the optimal treatment choice or sequence for later-line therapies due to a lack of clearly defined prognostic indicators. This multicenter real-world analysis aimed to identify predictive factors related to the effectiveness of FTD/TPI + Bev. PATIENTS AND
methodsWe retrospectively analyzed the medical records from our institution and collaborating centers of 71 mCRC patients given FTD/TPI + Bev as third-line or later treatment. Survival data were calculated using the Kaplan-Meier method, and group comparisons were made using the log-rank test. Multivariate analyses of progression-free survival (PFS) and overall survival (OS) were performed using a Cox proportional-hazards model.
resultsA performance status (PS) of 0-1, absence of liver metastases, and fewer metastatic sites were significantly associated with improved PFS. For OS, significant differences were observed according to PS, presence of liver metastases, number of metastatic sites, and RAS/BRAF mutational status. Among patients who received anti-VEGF agents in second-line therapy, those with a second-line PFS of more than 9 months had significantly better median PFS and OS with FTD/TPI + Bev compared to those with a median PFS of 9 months or less. In multivariate analysis, PS and duration of second-line PFS were the only significant predictors of PFS and OS.
conclusionThe response to anti-VEGF agents in second-line therapy may predict the efficacy of FTD/TPI + Bev in subsequent treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.